SY‑079 / Syros, Dana-Farber Cancer Institute - LARVOL DELTA

Qurient “Q901 slows down ADC resistance through combined use of ‘TOP1’ inhibitor” [Google translation] (Hankyung) - "In this study, NCI used the TOP1 inhibitor ‘Topotecan’ and the CDK7 inhibitor ‘THZ1’ in combination. The results of the study showed that topotecan induced cell death by producing TOP1-induced DNA cleavage and DNA-protein cross-linking (TOP1-DPC), which requires protein degradation by the ubiquitin-proteasome pathway (UPP). THZ1 induced ubiquitin-mediated proteasomal degradation of RNA polymerase II (Pol II degradation) and blocked UPP-mediated TOP1-DPC degradation....Based on these research results, NCI selected Qurient's 'Q901' among the CDK7 inhibitors under clinical development and began joint development."

Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor